Capstone Investment Advisors
CYTK icon

Capstone Investment Advisors’s Cytokinetics CYTK Stock Holding History

Capstone Investment Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-153,900
Closed -$12.8M – 2376
2023
Q4 		$12.8M Buy
153,900
+114,900
+295% +$4.16M 0.04% 290
2023
Q3 		$1.15M Buy
+39,000
New +$1.3M 0.01% 933
2021
Q1 		– Sell
-35,000
Closed -$727K – 1728
2020
Q4 		$727K Buy
+35,000
New +$640K ﹤0.01% 1168

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Capstone Investment Advisors's CYTK Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 12,094 shares — an estimated $665K sold.

Capstone Investment Advisors first reported a position in CYTK in Q3 2025 and held it in 1 quarter. The position peaked at $665K in Q3 2025. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 12,094 Cytokinetics shares in Q4 2025, an estimated $665K.
  • Capstone Investment Advisors first reported a position in Cytokinetics in Q3 2025 and held it in 1 quarter.
  • Capstone Investment Advisors's Cytokinetics position peaked at $665K in Q3 2025.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.